2. Search Result
Search Result
Results for "

artery

" in MedChemExpress (MCE) Product Catalog:

304

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

8

Biochemical Assay Reagents

34

Peptides

3

Inhibitory Antibodies

29

Natural
Products

18

Isotope-Labeled Compounds

3

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14654
    Aspirin
    30+ Cited Publications

    Acetylsalicylic acid; ASA

    		 Environmental Pollutants Autophagy NF-κB Apoptosis COX Mitophagy Virus Protease Caspase p38 MAPK Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin
  • HY-B1788
    Taurocholic acid
    Maximum Cited Publications
    31 Publications Verification

    N-Choloyltaurine

    		 Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
    Taurocholic acid
  • HY-15283
    Clopidogrel
    25+ Cited Publications

    Clopidogrelum

    		 P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
    Clopidogrel
  • HY-N0545
    Taurocholic acid sodium
    Maximum Cited Publications
    31 Publications Verification

    Sodium taurocholate; N-Choloyltaurine sodium

    		 VEGFR Endogenous Metabolite Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
    Taurocholic acid sodium
  • HY-B0203A
    Nebivolol hydrochloride
    3 Publications Verification

    R 065824 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol hydrochloride
  • HY-I0400
    N-Acetylneuraminic acid
    5 Publications Verification

    NANA; Lactaminic acid

    		 Tyrosinase Ras Influenza Virus Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    N-Acetylneuraminic acid
  • HY-B1131
    Taurocholic acid sodium salt hydrate
    Maximum Cited Publications
    31 Publications Verification

    Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate

    		 Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    Taurocholic acid (N-Choloyltaurine) sodium salt hydrate has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium salt hydrate has immunoregulation effect .
    Taurocholic acid sodium salt hydrate
  • HY-12378
    BQ-123
    3 Publications Verification

    		 Endothelin Receptor Cardiovascular Disease
    BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC50 of 7.3 nM and a Ki of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .
    BQ-123
  • HY-17402
    Nisoldipine
    2 Publications Verification

    BAY-k 5552

    		 Calcium Channel Reactive Oxygen Species (ROS) Infection Cardiovascular Disease Neurological Disease
    Nisoldipine (BAY-k 5552; Sular) is an orally active and blood-brain barrier-penetrating dihydropyridine calcium antagonist, with greater vascular selectivity than other calcium channel antagonists. Nisoldipine inhibits calcium influx and blocks voltage-gated calcium channels. Nisoldipine dilates coronary and systemic arteries. Nisoldipine has antihypertensive and anti-anginal activity. Nisoldipine also displays neuroprotective and antiviral activity .
    Nisoldipine
  • HY-B0203
    Nebivolol
    3 Publications Verification

    R 065824

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol
  • HY-118284
    Vicagrel
    1 Publications Verification

    		 P2Y Receptor Cardiovascular Disease
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
    Vicagrel
  • HY-12424
    Zotarolimus
    4 Publications Verification

    ABT-578; A 179578

    		 Drug Derivative Cardiovascular Disease Inflammation/Immunology Cancer
    Zotarolimus (ABT-578) is a derivative of Rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis .
    Zotarolimus
  • HY-B1815
    Xanthinol Nicotinate

    Xanthinol Niacinate

    		 PDGFR Cardiovascular Disease
    Xanthinol Nicotinate (Xanthinol Niacinate), a vasodilator, can act directly on the smooth muscle of small arteries and capillaries. Xanthinol Nicotinate expands blood vessels, improves blood rheology and reduces peripheral vascular resistance .
    Xanthinol Nicotinate
  • HY-122908
    Atuliflapon

    AZD5718

    		 FLAP Cardiovascular Disease
    Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5?Lipoxygenase activating protein), with an IC50 of 2 nM. Atuliflapon is used in the study for coronary artery disease .
    Atuliflapon
  • HY-101369
    BW-723C86
    1 Publications Verification

    		 5-HT Receptor Cardiovascular Disease Neurological Disease
    BW-723C86 is an orally active and a selective 5-HT2B receptor agonist. BW-723C86 exhibits anxiolytic-like actions. BW-723C86 also causes hyperphagia and reduced grooming in rats. BW-723C86 dilates pulmonary arteries and inhibits liquid meal-induced gastric accommodation .
    BW-723C86
  • HY-12717A
    Phentolamine hydrochloride
    5+ Cited Publications

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Phentolamine hydrochloride is an orally active, selective α1 and α2 Adrenergic receptor antagonist. Phentolamine hydrochloride antagonizes the vasodilatory effect of Cromakalim (HY-110011) on isolated circumflex coronary artery segments in dogs. Phentolamine hydrochloride reduces systemic vascular resistance and increases cardiac output. Phentolamine hydrochloride improves erectile dysfunction. Phentolamine hydrochloride can be used for the research of erectile dysfunction .
    Phentolamine hydrochloride
  • HY-P1636
    Hirudin (54-65)

    		Thrombin YAP Calcium Channel Metabolic Disease
    Hirudin (54-65) is a thrombin antagonist and YAP suppressor with anticoagulatory properties.Hirudin (54-65) blocks thrombin's anion binding site, acts on soluble and thrombus-bound thrombin.Hirudin (54-65) suppresses thrombin-induced profibrotic YAP activity, reduces YAP expression, nuclear translocation, and downstream effector signaling in vascular endothelial cells.Hirudin (54-65) ameliorates obstructive cholestasis, attenuates liver fibrosis symptoms, fibrosis-associated angiogenesis, and endothelial-to-mesenchymal transition.Hirudin (54-65) reduces liver inflammation and tissue hypoxia.Hirudin (54-65) promotes extracellular calcium influx through L-type calcium channels in canine coronary artery smooth muscle, mediates contraction.Hirudin (54-65) induces endothelium-independent contraction of canine coronary arterial segments; this response is not affected by indomethacin pretreatment.Hirudin (54-65) can be used for the research of liver obstructive cholestasis, liver fibrosis .
    Hirudin (54-65)
  • HY-147323
    Ferulic acid 4-O-sulfate

    Ferulic acid 4-sulfate

    		 Drug Metabolite Cardiovascular Disease
    Ferulic acid 4-O-sulfate (Ferulic acid 4-sulfate) is a metabolite of Ferulic acid (HY-N0060). Ferulic acid 4-O-sulfate relaxes arteries and lowers blood pressure in mice .
    Ferulic acid 4-O-sulfate
  • HY-114672
    MBCQ

    		Phosphodiesterase (PDE) Cardiovascular Disease
    MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC50s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE .
    MBCQ
  • HY-N0545R
    Taurocholic acid sodium (Standard)
    5+ Cited Publications

    Sodium taurocholate (Standard); N-Choloyltaurine sodium (Standard)

    		 Reference Standards VEGFR Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid (sodium) (Standard) is the analytical standard of Taurocholic acid (sodium). This product is intended for research and analytical applications. Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
    Taurocholic acid sodium (Standard)
  • HY-P1112
    Sarafotoxin S6a

    		Endothelin Receptor Cardiovascular Disease Neurological Disease
    Sarafotoxin S6a, a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a elicits the pig coronary artery with an EC50 value of 7.5 nM .
    Sarafotoxin S6a
  • HY-123494
    BRD0418

    		CaMK Cardiovascular Disease Neurological Disease
    BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
    BRD0418
  • HY-B0813
    Treprostinil diethanolamine
    1 Publications Verification

    UT-15C

    		 Prostaglandin Receptor Endocrinology
    Treprostinil (UT-15C) diethanolamine is a potent EP2, DP1 and IP agonist with Ki values of 3.6, 4.4, 32.1, 212, 826, 2505 and 4680 nM for EP2, DP1, IP, EP1, EP4, EP3 and FP, respectively. Treprostinil (UT-15C) diethanolamine increases upregulation of cAMP toward maintaining homeostasis within the vasculature. Treprostinil (UT-15C) diethanolamine can result in vasodilatation of human pulmonary arteries .
    Treprostinil diethanolamine
  • HY-106954
    Upidosin

    Rec 15/2739; Recordati 15/2739; SB 216469

    		 Adrenergic Receptor Inflammation/Immunology
    Upidosin (Rec 15/2739) is an α-1 adrenoceptor (α-1 AR) antagonist. Upidosin shows moderate selectivity for the α-1A AR subtype. Upidosin shows uroselectivity in urethra and prostate with a Kb value of 2-3 nM higher than in ear artery and aorta with a Kb value of 20-100 nM. Upidosin inhibits [3H]prazosin binding to cloned human α-1A adrenergic receptor. Upidosin can be used for the research of urethral obstruction .
    Upidosin
  • HY-161104
    Kv2.1-IN-1
    1 Publications Verification

    		 Potassium Channel Apoptosis Cardiovascular Disease Neurological Disease
    Kv2.1-IN-1 is an orally active and blood-brain barrier penetrant Kv2.1 inhibitor with an IC50 of 0.07 μM. Kv2.1-IN-1 exhibits a selectivity >130 fold over other K +, Na +, and Ca 2+ ion channels. Kv2.1-IN-1 decreases the apoptosis of HEK293 cells induced by H2O2. Kv2.1-IN-1 produces significant neuroprotection efficacy in middle cerebral artery occlusion (MCAO) rat. Kv2.1-IN-1 can be used for the study of ischemic stroke .
    Kv2.1-IN-1
  • HY-13056
    SMND-309
    1 Publications Verification

    		 Drug Metabolite Neurological Disease
    SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats .
    SMND-309
  • HY-111804
    3',4'-Dihydroxyflavonol
    1 Publications Verification

    DiOHF

    		 NO Synthase Cardiovascular Disease Metabolic Disease
    3',4'-Dihydroxyflavonol (DiOHF) is an effective antioxidant, which reduces superoxide and improves nitric oxide (NO) function in diabetic rat mesenteric arteries .
    3',4'-Dihydroxyflavonol
  • HY-I0400R
    N-Acetylneuraminic acid (Standard)

    NANA (Standard); Lactaminic acid (Standard)

    		 Reference Standards Tyrosinase Ras Influenza Virus Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    N-Acetylneuraminic acid (Standard) is the analytical standard of N-Acetylneuraminic acid. This product is intended for research and analytical applications. N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    N-Acetylneuraminic acid (Standard)
  • HY-100613
    MONNA

    		Chloride Channel Cardiovascular Disease
    MONNA is a potent transmembrane protein 16A (TMEM16A, Anoctamin-1) blocker with an IC50 of 80 nM. MONNA induces vasorelaxation of rodent resistance arteries in presence or absence of chloride ions .
    MONNA
  • HY-P1564A
    [Sar1, Ile8]-Angiotensin II TFA

    		Angiotensin Receptor Others
    [Sar1, Ile8]-Angiotensin II (TFA) is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.
    [Sar1, Ile8]-Angiotensin II TFA
  • HY-124304
    Pinokalant

    LOE-908

    		 TRP Channel SARS-CoV Neurological Disease
    Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity .
    Pinokalant
  • HY-P991574
    MEDI-5884

    REG-101

    		 ATGL Cardiovascular Disease
    MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .
    MEDI-5884
  • HY-103653
    CKD-731

    		MetAP Cardiovascular Disease Cancer
    CKD-731 is a Fumagillin (HY-B0751) analogue. CKD-731 inhibits the proliferation of calf pulmonary artery endothelial cells (CPAE), lymphoma EL-4 cells and murine leukemia P388D1 cells. CKD-731 exerts the effect of inhibiting MetAP-2 activity and blocking angiogenesis. CKD-731 can be used for the research of anti-angiogenesis-related cancer .
    CKD-731
  • HY-101393A
    CGP 12177 hydrochloride

    (±)-CGP 12177 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    CGP 12177 ((±)-CGP 12177) hydrochloride is a β-Adrenergic receptor (β-AR) ligand. CGP 12177 hydrochloride is a β3-AR (Ki = 88 nM) agonist with β1/β2-AR (Ki = 0.9 nM for β1; Ki = 4 nM for β2) antagonist action. CGP 12177 hydrochloride exhibits partial agonist properties for α1-AR in rat pulmonary artery. CGP 12177 hydrochloride regulates the expression of ucp and leptin genes in NMRI mice adipose tissues. CGP 12177 hydrochloride can be used for cardiovascular and metabolic disease research [1][2][3][4].
    CGP 12177 hydrochloride
  • HY-118332
    19(R)-HETE

    		Prostaglandin Receptor Cardiovascular Disease
    19(R)-HETE is a vasodilator in renal arteries, whereas 19(S)-HETE was relatively inactive .
    19(R)-HETE
  • HY-P3563
    [Lys4] Sarafotoxin S6c

    		Endothelin Receptor Cardiovascular Disease
    [Lys4] Sarafotoxin S6c, a sarafotoxin analogue, is a potent and partial agonist of endothelin receptor. [Lys4] Sarafotoxin S6c elicits contraction of pig coronary artery, with an EC50 of 1.5 nM .
    [Lys4] Sarafotoxin S6c
  • HY-15378
    Talibegron hydrochloride

    ZD2079 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    Talibegron hydrochloride (ZD2079 hydrochloride) is a potent β3-adrenoceptor agonist with a pD2 of 3.72 on phenylephrine-preconstricted rat mesenteric artery. Talibegron hydrochloride has potent vasorelaxant effect .
    Talibegron hydrochloride
  • HY-W704079
    1-Stearoyl-sn-glycerol

    ​MG(18:0/0:0/0:0); L-(+)-1-Monostearin; 1-Octadecanoyl-sn-glycerol

    		 Endogenous Metabolite Cardiovascular Disease
    1-Stearoyl-sn-glycerol is (MG(18:0/0:0/0:0); L-(+)-1-Monostearin; 1-Octadecanoyl-sn-glycerol) is a monoglyceride and also a metabolite found in plasma, which can be used in metabolomic analysis of plasma for coronary artery lesions (CAL) .
    1-Stearoyl-sn-glycerol
  • HY-B1788R
    Taurocholic acid (Standard)

    N-Choloyltaurine (Standard)

    		 Reference Standards Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
    Taurocholic acid (Standard)
  • HY-126049
    (S)-Oxiracetam

    (S)-(-)-Oxiracetam; (S)-ISF2522

    		 Apoptosis Neurological Disease
    (S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .
    (S)-Oxiracetam
  • HY-108564
    L 655240

    		Prostaglandin Receptor Cardiovascular Disease
    L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders .
    L 655240
  • HY-P3433
    Sarafotoxin S6b

    		Endothelin Receptor Cardiovascular Disease
    Sarafotoxin S6b is a vasoconstrictor peptide, and a non-selective endothelin receptor agonist. Sarafotoxin S6b can induce contraction in isolated human coronary arteries , the Ki values of Coronary artery, Saphenous vein and Coronary artery are 0.27, 0.55 and 19.5 nM, respectively .
    Sarafotoxin S6b
  • HY-177948
    GRK2 degrader-1

    		G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease
    GRK2 degrader-1 (compound 1) is a potent and orally active GRK2 degrader. GRK2 degrader-1 degrades GRK2 via the ubiquitin-proteasome pathway. GRK2 degrader-1 inhibits right ventricular remodeling and elevation of pulmonary artery pressure in a pulmonary artery hypertension (PAH) mouse model. GRK2 degrader-1 can be used for PAH research .
    GRK2 degrader-1
  • HY-122331
    Norbormide

    		Environmental Pollutants Calcium Channel Cardiovascular Disease
    Norbormide, a rodenticide, is a calcium entry blocker with a selective vasoconstrictor activity. Norbormide shows species- and tissue-specific, endothelium independent, and is restricted to the peripheral arteries of rat .
    Norbormide
  • HY-B1815R
    Xanthinol Nicotinate (Standard)

    Xanthinol Niacinate (Standard)

    		 PDGFR Reference Standards Cardiovascular Disease
    Xanthinol Nicotinate (Standard) is the analytical standard of Xanthinol Nicotinate. This product is intended for research and analytical applications. Xanthinol Nicotinate (Xanthinol Niacinate), a vasodilator, can act directly on the smooth muscle of small arteries and capillaries. Xanthinol Nicotinate expands blood vessels, improves blood rheology and reduces peripheral vascular resistance .
    Xanthinol Nicotinate (Standard)
  • HY-100206
    5α-Androstane-3β,5,6β-triol

    		AMPK Neurological Disease
    5α-Androstane-3β,5,6β-triol is a neuroprotectant. 5α-Androstane-3β,5,6β-triol can remarkably reverse intracellular acidification and alleviate neuronal injury through the inhibition of AMPK signaling. 5α-Androstane-3β,5,6β-triol remarkably reduced the infarct volume and attenuated neurologic impairment in acute ischemic stroke models of middle cerebral artery occlusion in vivo .
    5α-Androstane-3β,5,6β-triol
  • HY-14654C
    Aspirin calcium

    Acetylsalicylic acid calcium; ASA calcium

    		 COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    Aspirin calcium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin calcium induces apoptosis. Aspirin calcium inhibits the activation of NF-κB. Aspirin calcium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin calcium
  • HY-14654A
    Aspirin lithium

    Acetylsalicylic acid lithium; ASA lithium

    		 COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin lithium
  • HY-U00147
    Nicotinoyl cyclandelate

    RV 12128

    		 Biochemical Assay Reagents Cardiovascular Disease
    Nicotinoyl cyclandelate can be used to lower the perfusion pressure of cerebral blood vessels and the blood pressure of femoral artery.
    Nicotinoyl cyclandelate
  • HY-101393
    CGP 12177

    (±)-CGP 12177

    		 Adrenergic Receptor Cardiovascular Disease Metabolic Disease
    CGP 12177 ((±)-CGP 12177) is a β-Adrenergic receptor (β-AR) ligand. CGP 12177 is a β3-AR (Ki = 88 nM) agonist with β1/β2-AR (Ki = 0.9 nM for β1; Ki = 4 nM for β2) antagonist action. CGP 12177 exhibits partial agonist properties for α1-AR in rat pulmonary artery. CGP 12177 regulates the expression of ucp and leptin genes in NMRI mice adipose tissues. CGP 12177 can be used for cardiovascular and metabolic disease research .
    CGP 12177

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: